Literature DB >> 27056935

Antiphospholipid Antibodies and Renal Impairment Parameters in Diabetic Nephropathy: Preliminary Data.

Mirjana Bećarević1,2, Velibor Čabarkapa1,3, Mirjana Đerić1,3, Svetlana Ignjatović2,4.   

Abstract

OBJECTIVE: Antiphospholipid antibodies (aPL Abs) represented an independent factor that was associated with the occurrence and/or progression of nephropathy in patients with antiphospholipid syndrome, but their role in diabetic nephropathy is not elucidated. Therefore, we evaluated the association of aPL Abs with the renal impairment parameters in patients with diabetic nephropathy.
METHODS: Concentrations of analyzed antibodies were measured by enzyme-linked immunosorbent assay.
RESULTS: Cystatin C and anticardiolipin (aCL) antibodies of the immunoglobulin (Ig) G ( r = .349, P = .004) and the IgM isotype ( r = .316, P = .009) were in positive correlation. The IgG isotype of the aCL Abs was in positive correlation with creatinine ( r = .252, P = .038), urea ( r = .241, P = .048), and uric acid ( r = .271, P = .025). The concentrations of the IgG isotype of the aCL Abs were significantly different between subgroups of patients with diabetic polyneuropathy and patients without this clinical finding (Mann-Whitney, P = .033).
CONCLUSION: This is the first report on positive correlation between aCL Abs and renal impairment parameters. Larger studies are necessary for elucidation whether this association is involved in further progression of the disease.

Entities:  

Keywords:  anti-β2glycoprotein I antibodies; anticardiolipin antibodies; cystatin C; diabetic nephropathy; diabetic polyneuropathy

Mesh:

Substances:

Year:  2016        PMID: 27056935     DOI: 10.1177/1076029616642512

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  1 in total

1.  Iopromide and Iodixanol in the Development of Postoperative Contrast Nephropathy in Patients with Renal Insufficiency: A Meta-Analysis.

Authors:  Yiyu Feng; Guoping Qiu; Chengyun Xu; Zhibing Duan; Manting Wang; Lamei Wang; Wenjie Hu; Peifang Li; Hui Zhou
Journal:  J Healthc Eng       Date:  2022-04-05       Impact factor: 2.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.